Market Overview

Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc.

Share:

WAYNE, Pa., Dec. 9, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cubist Pharmaceuticals Inc. ("Cubist" or the "Company") (NASDAQ: CBST) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Merck & Co., Inc. in a transaction valued at approximately $9.5 billion.

Ryan & Maniskas, LLP

If you own shares of Cubist and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/cbst. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com

Under the terms of the agreement, shareholders of Cubist would receive $102.00 per share in cash for each share of Cubist they own. 

Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist for not acting in the Company's shareholders' best interests in connection with the sale process. 

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.  To learn more about the class action process, please visit: www.rmclasslaw.com.

CONTACT: 
Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/cbst          
rmaniskas@rmclasslaw.com 

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-investigation-of-cubist-pharmaceuticals-inc-300006936.html

SOURCE Ryan & Maniskas, LLP

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com